Jeffrey Fudin, PharmD, DAIPM, FCCP, FASHP

The FDA approved cannabidiol (CBD) last year for the treatment of seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged 2 years and older. As pharmacists, we will likely be called upon as experts in CBD therapeutics.

Emgality (Galcanezumab-gnlm) is a self-administered once monthly subcutaneous injection and the third in its class for the preventative treatment of migraine in adults.

Millions worldwide dread the onset of debilitating migraines. There is a new drug class on the horizon that is thought to put a stop to the root of migraines.

Despite a decline in the rate of opioid prescribing, the CDC reports that the number of opioid related deaths continues to rise. The pharmacology and pharmacokinetics of prescription and illicit fentanyl could help to shed light on why the opioid epidemic has taken the path that it has.

Opioid allergies are often misdiagnosed. Improper allergy diagnosis may lead to delays in treatment and unnecessary drug avoidance.

A look at the different receptor bindings that affect analgesic effect.

The established therapeutic dosing for gabapentin in neuropathic pain is 1800-3600 mg/day in 3 divided doses in patients with normal renal function.

Here is how to distinguish between those who need prescriptions to manage pain and those seeking controlled substances for illicit reasons.

This testing has a positive clinical and therapeutic impact on dosage requirements and ethical considerations.